Treatment of Melasma Using Q-switched Nd: YAG Laser and Fractional CO2 Laser Separately and in Combination
NCT ID: NCT03848013
Last Updated: 2020-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2017-01-31
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Group A will be subjected to 3 consecutive sessions of Q-switched 1,064 nm Nd: YAG laser to one side of the face \& fractional co2 laser to the other side of the face with one month interval between sessions.
* Group B will be subjected also to 3 consecutive sessions of Q-switched 1,064 nm Nd: YAG laser to one side of the face \& an additional fractional co2 laser to the other side of the face using the above mentioned parameters with one month interval between sessions.
* Response to treatment will be assessed using the Melanin Index (MI) score, Melasma Area and Severity Index (MASI) score, spectrophotometer ( Derma catch, colorix, Neuchatel, Switzerland ) and a subjective self-assessment method.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma
NCT02892071
Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System
NCT00955461
Comparative Effects Of Trichloroacetic Chemical Peel And Fractional Laser
NCT07036302
Fractional CO2 Laser Combined With PRP Fluid Versus Gel in Treatment of Acne Scars
NCT04580758
Autologous Plasma Gel Injection Versus Polydioxanone Cog Threads Insertion for the Treatment of Atrophic Post-acne Scars: a Split-face
NCT06580691
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Treatment of cases of melasma using Q switched Nd YAG laser and Fractional CO2 laser separately and in combination
Q switched Nd YAG laser
Laser device emitting Q switched Nd YAG aiming for skin toning
Fractional CO2 laser
Laser device emitting fractionated ablative laser aiming for skin resurfacing
Follow -up period
follow up of the treated cases for 2 months
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Q switched Nd YAG laser
Laser device emitting Q switched Nd YAG aiming for skin toning
Fractional CO2 laser
Laser device emitting fractionated ablative laser aiming for skin resurfacing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Usage of chemical peeling 1 month prior to the study.
* Isotretinoin intake 6 months prior to the study.
* Any laser procedure related to melasma lesions 1 month prior to the study.
* Active herpetic lesions.
* Any concurrent active skin disease within the treated area.
* Photosensitive skin conditions such as systemic lupus erythematous.
* History of delayed wound healing.
* Keloid formation.
* Bleeding diathesis.
* Medical conditions such as diabetes mellitus \& autoimmune diseases.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rana F Hilal, MD
Lecturer of dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cairo University Kasr Al Ainy Hospital Dermatology department
Cairo, El Manial, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CairoU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.